For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

Prospects for the drug had already suffered a blow in 2022, when it did not slow disease progression when tested on a ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 ...

Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer ...

Roche is to end a novel lung cancer treatment trial, the Swiss company confirmed on Thursday, following "disappointing" ...

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting ...

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared ...

A tracer known as FAPI performed better than the commonly used 18F-FDG for capturing early signs of pulmonary fibrosis on PET ...

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for ...

Bronchitis causes a wet cough that can last for weeks. People with COPD may experience chronic bronchitis flares. Learn how ...

What is the life expectancy of someone with interstitial lung disease? Answered by Dr. Howard E. Lewine M.D. Chief Medical ...

A flawed new algorithm for distributing lungs to transplant patients wound up putting people with Type O blood at a ...